Persistent Chemosensitivity to Platinum and/or Paclitaxel in Metastatic Endometrial Cancer

This publication has 11 references indexed in Scilit:

• Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1998
• “Recurrence within 6 Months of Platinum Therapy”: An Adequate Definition of “Platinum-Refractory” Ovarian Cancer?
  Gynecologic Oncology, 1998
• Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
  Journal of Clinical Oncology, 1998
• A Phase II Trial of Paclitaxel in Patients with Advanced or Recurrent Adenocarcinoma of the Endometrium: A Gynecologic Oncology Group Study
  Gynecologic Oncology, 1996
• Endometrial Carcinoma
  New England Journal of Medicine, 1996
• The ‘failure free interval’ defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing
  International Journal of Gynecologic Cancer, 1991
• Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions.
  Journal of Clinical Oncology, 1991
• Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
  Journal of Clinical Oncology, 1991
• Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
  Gynecologic Oncology, 1990
• Prolonged Disease-Free Survival in Hodgkin's Disease with MOPP Reinduction After First Relapse
  Annals of Internal Medicine, 1979